priors.science/reviews/colorectal-cancer-targeted-immunotherapy

Colorectal Cancer Targeted Immunotherapy

The current evidence on 10 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

10claims tracked
100primary papers reviewed
4 Jun 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 2 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StablePembrolizumab first-line in microsatellite instability-high metastatic colorectal cancerMsi ImmunoEstablished90%10
StableRAS mutation predicts no anti-EGFR benefitEGFR RasEstablished90%10
StableNivolumab plus ipilimumab in microsatellite instability-high colorectal cancerMsi ImmunoEstablished88%10
StableEncorafenib plus cetuximab in BRAF V600E-mutant colorectal cancerBraf HER2Established88%10
StableAdjuvant oxaliplatin-based chemotherapy in stage III colon cancerEarly StageEstablished88%10
StableAnti-EGFR therapy in left-sided RAS wild-type colorectal cancerEGFR RasEstablished86%10
StableNeoadjuvant immunotherapy in mismatch repair-deficient colon cancerEarly StageEstablished86%10
StableSecond-line ramucirumab or afliberceptVegf AntiLikely82%10
StableHER2-targeted therapy in HER2-amplified colorectal cancerBraf HER2Likely80%10
StableBevacizumab first-line overall survivalVegf AntiUncertain60%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic